A biotech campus underway in Millbrae secured its first major tenant, with drug developer Eikon Therapeutics announcing it had signed a lease for 285,000 square feet, nearly half of the four-building Alexandra campus that broke ground this year near the train station.
It’s the first major lease announcement for the city of 22,000 that recently began ushering in life-science developments in hopes of steering the booming industry — and its tax revenue — to the mostly residential Peninsula suburb.
Eikon estimates its leased space, made up of both office and lab room, will accommodate 750 employees. The complete campus, planned for completion in 2024, is designed for approximately 2,000 workers. Founded in May 2021, the company said it analyzes single molecule protein behavior in living cells for drug discovery through engineering and computing. Co-founder Eric Betzig won the Nobel Prize in chemistry in 2014 for his pioneering work in super-resolution microscopy.
The move will shift Eikon’s headquarters from Hayward to Millbrae, the company said.
“We are proud to expand our presence in the region,” Eikon CEO Roger Perlmutter said. “We look forward to working with Alexandria to create an inspiring space where our multidisciplinary teams can even more effectively pursue our mission of delivering therapies that will improve and extend life.”
The Alexandra campus merges several lots, with addresses including 231 Millbrae Ave., 6, 20 and 30 Rollins Road, and 201, 230 and 231 Adrian Road. Adjacent, at 210 Adrian Road, replacing a self storage facility, a 263,000-square-foot biotech building is planned to break ground this year, also for a 2024 completion.
“It is an exciting time of future-looking development in our city, and we look forward to welcoming the entire Eikon team to our community,” City Manager Tom Williams, said.
Keep the discussion civilized. Absolutely NO
personal attacks or insults directed toward writers, nor others who
make comments. Keep it clean. Please avoid obscene, vulgar, lewd,
racist or sexually-oriented language. Don't threaten. Threats of harming another
person will not be tolerated. Be truthful. Don't knowingly lie about anyone
or anything. Be proactive. Use the 'Report' link on
each comment to let us know of abusive posts. PLEASE TURN OFF YOUR CAPS LOCK. Anyone violating these rules will be issued a
warning. After the warning, comment privileges can be
revoked.
Please purchase a Premium Subscription to continue reading.
To continue, please log in, or sign up for a new account.
We offer one free story view per month. If you register for an account, you will get two additional story views. After those three total views, we ask that you support us with a subscription.
A subscription to our digital content is so much more than just access to our valuable content. It means you’re helping to support a local community institution that has, from its very start, supported the betterment of our society. Thank you very much!
(0) comments
Welcome to the discussion.
Log In
Keep the discussion civilized. Absolutely NO personal attacks or insults directed toward writers, nor others who make comments.
Keep it clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't threaten. Threats of harming another person will not be tolerated.
Be truthful. Don't knowingly lie about anyone or anything.
Be proactive. Use the 'Report' link on each comment to let us know of abusive posts.
PLEASE TURN OFF YOUR CAPS LOCK.
Anyone violating these rules will be issued a warning. After the warning, comment privileges can be revoked.